Rainer Kuefer

Summary

Affiliation: University of Ulm
Country: Germany

Publications

  1. pmc Antagonistic effects of sodium butyrate and N-(4-hydroxyphenyl)-retinamide on prostate cancer
    Rainer Kuefer
    Department of Urology and the Comprehensive Cancer Center Ulm, University of Ulm, 89075 Ulm, Germany
    Neoplasia 9:246-53. 2007
  2. ncbi request reprint [Introduction to the topic: molecular biological elucidation of renal cell carcinoma]
    R Kufer
    Urologische Klinik, Universitat Ulm
    Urologe A 45:295-6. 2006
  3. doi request reprint POU5F1P1, a putative cancer susceptibility gene, is overexpressed in prostatic carcinoma
    Silvia Kastler
    Institute of Human Genetics, University of Ulm, Ulm, Germany
    Prostate 70:666-74. 2010
  4. doi request reprint [11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study
    Ludwig Rinnab
    Department of Urology, University of Ulm, Ulm, Germany
    Urol Int 81:191-7. 2008
  5. doi request reprint Expression changes of CAV1 and EZH2, located on 7q31 approximately q36, are rarely related to genomic alterations in primary prostate carcinoma
    Natascha Bachmann
    Department of Human Genetics, University of Ulm, Albert Einstein Allee 11, 89081 Ulm, Germany
    Cancer Genet Cytogenet 182:103-10. 2008
  6. ncbi request reprint Intensifying the saturation biopsy technique for detecting prostate cancer after previous negative biopsies: a step in the wrong direction
    Jörg Simon
    Department of Urology, University of Ulm, Ulm, and Krankenhaus Göttingen Weende, Gottingen, Germany
    BJU Int 102:459-62. 2008
  7. pmc RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease
    Kilian M Gust
    Department of Urology, University of Ulm, Ulm, Germany
    Neoplasia 11:956-63. 2009
  8. ncbi request reprint Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer
    Ludwig Rinnab
    Department of Urology, University of Ulm, Ulm, Germany
    BJU Int 100:786-93. 2007
  9. ncbi request reprint Nosocomial bacteriuria in patients with indwelling catheter after radical retropubic prostatectomy for prostate cancer
    Georg C Bartsch
    Department of Urology, University of Ulm, Ulm, Germany
    Urol Int 81:389-93. 2008
  10. doi request reprint Oncological followup after radical cystectomy for bladder cancer-is there any benefit?
    Bjoern G Volkmer
    Department of Urology, University of Ulm, Ulm, Germany
    J Urol 181:1587-93; discussion 1593. 2009

Collaborators

Detail Information

Publications36

  1. pmc Antagonistic effects of sodium butyrate and N-(4-hydroxyphenyl)-retinamide on prostate cancer
    Rainer Kuefer
    Department of Urology and the Comprehensive Cancer Center Ulm, University of Ulm, 89075 Ulm, Germany
    Neoplasia 9:246-53. 2007
    ..These results indicate that combinational therapies have to be carefully investigated due to potential antagonistic effects in the clinical setting despite promising results of a monotherapy...
  2. ncbi request reprint [Introduction to the topic: molecular biological elucidation of renal cell carcinoma]
    R Kufer
    Urologische Klinik, Universitat Ulm
    Urologe A 45:295-6. 2006
  3. doi request reprint POU5F1P1, a putative cancer susceptibility gene, is overexpressed in prostatic carcinoma
    Silvia Kastler
    Institute of Human Genetics, University of Ulm, Ulm, Germany
    Prostate 70:666-74. 2010
    ..The objective of this study was to investigate the POU5F1P1 expression in prostatic carcinoma and carcinoma surrounding prostatic tissue...
  4. doi request reprint [11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study
    Ludwig Rinnab
    Department of Urology, University of Ulm, Ulm, Germany
    Urol Int 81:191-7. 2008
    ..In this prospective study we set out to investigate the diagnostic value of [(11)C]choline-PET/CT in patients with suspected lymph node metastases before salvage lymph node dissection...
  5. doi request reprint Expression changes of CAV1 and EZH2, located on 7q31 approximately q36, are rarely related to genomic alterations in primary prostate carcinoma
    Natascha Bachmann
    Department of Human Genetics, University of Ulm, Albert Einstein Allee 11, 89081 Ulm, Germany
    Cancer Genet Cytogenet 182:103-10. 2008
    ..Through bisulfite sequencing of four tumor samples, CpG-hypermethylation was verified as an alternative mechanism for CAV1 silencing, as reported previously. Moreover, it could also be involved in the reactivation of EZH2...
  6. ncbi request reprint Intensifying the saturation biopsy technique for detecting prostate cancer after previous negative biopsies: a step in the wrong direction
    Jörg Simon
    Department of Urology, University of Ulm, Ulm, and Krankenhaus Göttingen Weende, Gottingen, Germany
    BJU Int 102:459-62. 2008
    ..To report the results using an extensive saturation biopsy in men with negative prostate biopsies but in whom there is still a clinical suspicion for carcinoma...
  7. pmc RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease
    Kilian M Gust
    Department of Urology, University of Ulm, Ulm, Germany
    Neoplasia 11:956-63. 2009
    ..Acknowledging the proven immunogenic effects of RHAMM in leukemia, this antigen is intriguing as a therapeutic target in far-advanced CaP...
  8. ncbi request reprint Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer
    Ludwig Rinnab
    Department of Urology, University of Ulm, Ulm, Germany
    BJU Int 100:786-93. 2007
    ..To evaluate [(11)C]-choline positron-emission tomography (PET)/computed tomography (CT) for detecting clinical recurrence after primary treatment for prostate cancer...
  9. ncbi request reprint Nosocomial bacteriuria in patients with indwelling catheter after radical retropubic prostatectomy for prostate cancer
    Georg C Bartsch
    Department of Urology, University of Ulm, Ulm, Germany
    Urol Int 81:389-93. 2008
    ..Patients with prolonged catheter drainage following pelvic surgery are at increased risk for bacteriuria that may have an impact on the clinical course...
  10. doi request reprint Oncological followup after radical cystectomy for bladder cancer-is there any benefit?
    Bjoern G Volkmer
    Department of Urology, University of Ulm, Ulm, Germany
    J Urol 181:1587-93; discussion 1593. 2009
    ..To our knowledge it is still unknown whether detecting tumor recurrence at an asymptomatic stage offers a better survival rate...
  11. doi request reprint Upper urinary tract recurrence after radical cystectomy for bladder cancer--who is at risk?
    Bjoern G Volkmer
    Department of Urology, University of Ulm, Ulm, Germany
    J Urol 182:2632-7. 2009
    ..Patients who underwent radical cystectomy for bladder cancer are at risk for upper urinary tract recurrence. We identified subgroups of patients at increased risk for upper urinary tract recurrence...
  12. ncbi request reprint Hydronephrosis as a prognostic marker in bladder cancer in a cystectomy-only series
    Georg C Bartsch
    Department of Urology, Faculty of Medicine, University of Ulm, Ulm, Germany
    Eur Urol 51:690-7; discussion 697-8. 2007
    ..This study investigated the prognostic impact of hydronephrosis in bladder cancer...
  13. ncbi request reprint Effect of a pT0 cystectomy specimen without neoadjuvant therapy on survival
    Bjoern G Volkmer
    Department of Urology, University of Ulm, Germany
    Cancer 104:2384-91. 2005
    ..In some cases of radical cystectomy for bladder cancer, no residual tumor is found in the cystectomy specimen (the pT0 classification). The aim of this study was to evaluate the outcome of such patients in a large cystectomy series...
  14. ncbi request reprint High-flow priapism: a combined interventional approach with angiography and colour Doppler
    Bjoern G Volkmer
    Department of Urology, Faculty of Medicine, University of Ulm, Germany
    Ultrasound Med Biol 28:165-9. 2002
    ..The procedure also prevents an occlusion of intact arteries that affects the penile perfusion and increases the risk of erectile dysfunction...
  15. ncbi request reprint Mutation screen and association study of EZH2 as a susceptibility gene for aggressive prostate cancer
    Natascha Bachmann
    Department of Human Genetics, University of Ulm, Ulm, Germany
    Prostate 65:252-9. 2005
    ..This report details the results of the first mutation screen and association study of EZH2 (located at 7q35) as a potential candidate gene for the development of aggressive prostate cancer...
  16. ncbi request reprint Pathological T0 prostate cancer without neoadjuvant therapy: clinical presentation and follow-up
    Kathleen Herkommer
    Department of Urology, Faculty of Medicine, University of Ulm, Prittwitzstrasse 43, 89075, Ulm, Germany
    Eur Urol 45:36-41. 2004
    ..In a small group of patients no tumour can be found in the radical prostatectomy specimen. These cases are classified as stage pT0. The aim of this study was to evaluate the clinical presentation of this entity and their prognosis...
  17. ncbi request reprint Influence of nitrate levels in drinking water on urological malignancies: a community-based cohort study
    Bjoern G Volkmer
    Department of Urology, University of Ulm, Ulm, Germany
    BJU Int 95:972-6. 2005
    ..To evaluate the effect of nitrate levels in the drinking water on the incidence of urological malignancies in a German community...
  18. ncbi request reprint High-flow priapism: colour-Doppler ultrasound-guided supraselective embolization therapy
    Georg Bartsch
    Department of Urology, Faculty of Medicine, University of Ulm, Prittwitzstrasse 43, 89075 Ulm, Germany
    World J Urol 22:368-70. 2004
    ....
  19. pmc ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease
    Rainer Kuefer
    Department of Urology and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109 0944, USA
    Neoplasia 8:319-29. 2006
    ..These results suggest that ADAM15 is generally overexpressed in adenocarcinoma and is highly associated with metastatic progression of prostate and breast cancers...
  20. ncbi request reprint Prognostic factors in lymph node-positive prostate cancer
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Urology 67:1016-21. 2006
    ..The incidence of clinically localized PCa with concurrent lymph node metastasis has decreased to less than 1% in the United States but is between 10% and 15% in other countries...
  21. pmc Defining aggressive prostate cancer using a 12-gene model
    Tarek A Bismar
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    Neoplasia 8:59-68. 2006
    ..0015). This study demonstrates that cross-platform models can lead to predictive models with the possible advantage of being more robust through this selection process...
  22. pmc alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation
    Rainer Kuefer
    Department of Pathology, University of Michigan Medical School, Ann Arbor 48109 0602, USA
    Am J Pathol 161:841-8. 2002
    ..Taken together, these data suggest that AMACR expression is not hormone-dependent but may in fact be a marker of tumor differentiation...
  23. ncbi request reprint The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer
    Rainer Kuefer
    Department of Urology, University of Michigan Medical School, Ann Arbor, Michigan 48109 0944, USA
    Clin Cancer Res 9:6447-52. 2003
    ..The purpose of this study was to evaluate an 80 kDa proteolytic fragment of E-cadherin as a potential biomarker for prostate cancer progression and to identify putative proteases that are responsible for the cleavage of E-cadherin...
  24. ncbi request reprint The role of metastasis-associated protein 1 in prostate cancer progression
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Cancer Res 64:825-9. 2004
    ..In summary, this study identified an association of MTA1 expression and prostate cancer progression...
  25. pmc Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital, and the Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Pathol 164:831-40. 2004
    ..In the future, the AMACR AQUA Z-score may be useful in the automated screening and evaluation of prostate tissue biomarkers...
  26. ncbi request reprint Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer Res 64:3814-22. 2004
    ..In summary, these findings suggest that dysregulation of TPD52 by genomic amplification and androgen induction may play a role in prostate cancer progression...
  27. ncbi request reprint The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells
    Jonathan Rios-Doria
    Department of Urology, University of Michigan, Ann Arbor 48109, USA
    J Biol Chem 278:1372-9. 2003
    ..These findings demonstrate a novel mechanism by which E-cadherin is functionally inactivated through calpain-mediated proteolysis and suggests that E-cadherin is targeted by calpain during the tumorigenic progression of prostate cancer...
  28. ncbi request reprint Cathepsin D serum levels are not a valid serum marker in renal cell carcinoma
    Axel S Merseburger
    Department of Urology, Eberhard Karls University Tuebingen, Tuebingen, Germany
    Urol Int 79:41-3. 2007
    ..It was the aim of this study to evaluate the serum levels of cathepsin D (Cath D) as a diagnostic tool in patients with renal cell carcinoma (RCC) in comparison with healthy volunteers...
  29. ncbi request reprint Collagen XXIII expression is associated with prostate cancer recurrence and distant metastases
    Jacqueline Banyard
    Vascular Biology Program, Department of Surgery, Children s Hospital, Boston, MA 02115, USA
    Clin Cancer Res 13:2634-42. 2007
    ..The purpose of this study was to determine the expression of collagen XXIII in human prostate cancer and investigate its relationship with disease progression...
  30. ncbi request reprint Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
    Scott A Tomlins
    Department of Pathology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109 0602, USA
    Science 310:644-8. 2005
    ..These results have implications in the development of carcinomas and the molecular diagnosis and treatment of prostate cancer...
  31. ncbi request reprint Cleavage of beta-catenin by calpain in prostate and mammary tumor cells
    Jonathan Rios-Doria
    Cellular and Molecular Biology Graduate Program, Department of Urology, Michigan Urology Center, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, USA
    Cancer Res 64:7237-40. 2004
    ....
  32. ncbi request reprint Prostate-specific membrane antigen expression as a predictor of prostate cancer progression
    Sven Perner
    Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Hum Pathol 38:696-701. 2007
    ..6-9.7, P < .001, respectively). In summary, PSMA is independently associated with PSA recurrence in a high-risk cohort and thus might provide insight into the additional use of adjuvant therapy. Validation on other cohorts is required...
  33. pmc Genomic profiling of hormone-naïve lymph node metastases in patients with prostate cancer
    Pamela L Paris
    Department of Urology, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Neoplasia 8:1083-9. 2006
    ..Matched primaries and lymph node metastases showed very similar copy number profiles that are distinct from primary tumors that fail to metastasize...
  34. ncbi request reprint Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer
    Joanne N Davis
    Department of Urology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Cancer Res 66:11897-906. 2006
    ..Taken together, these results show that elevated E2F1, through its ability to repress AR transcription, may contribute to the progression of hormone-independent prostate cancer...
  35. ncbi request reprint TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer
    Sven Perner
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, EBRC 442A, 221 Longwood Avenue, Boston, MA 02115 6110, USA
    Cancer Res 66:8337-41. 2006
    ..The deletion as cause of TMPRSS2:ERG fusion is associated with clinical features for prostate cancer progression compared with tumors that lack the TMPRSS2:ERG rearrangement...
  36. ncbi request reprint 5-aza-2'-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer
    Christoph S Zorn
    Department of Urology, University of Michigan, Ann Arbor, Michigan 48109 0944, USA
    Clin Cancer Res 13:2136-43. 2007
    ..The purpose of this study was to determine the effect of 5-aza on preexisting TRAMP prostate cancers and prevention of androgen-independent prostate cancer...